前收市價 | 11.83 |
開市 | 11.70 |
買盤 | 12.03 x 900 |
賣出價 | 12.08 x 400 |
今日波幅 | 11.70 - 12.46 |
52 週波幅 | 10.87 - 83.60 |
成交量 | |
平均成交量 | 1,276,124 |
市值 | 1.297B |
Beta 值 (5 年,每月) | 0.43 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.95 |
業績公佈日 | 2024年5月02日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 27.33 |
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novocure announced encouraging results in a phase 3 trial for its TTFields therapy.
Novocure had good news mixed with some not-so-good news.